Literature DB >> 17897677

Motor complications in Parkinson disease: clinical manifestations and management.

Roongroj Bhidayasiri1, Daniel D Truong.   

Abstract

Long-term dopaminomimetic therapy, not limited to levodopa, is complicated by the emergence of variations of motor response in a majority of Parkinson disease (PD) patients. These variations can occur in different forms, as early wearing off during the initial stage of motor complications, dyskinesias in the intermediate stage, and complex fluctuations in the advanced stage. Considered to be a major source of disability in advanced PD patients, recognition of these complications is critical in order to develop different strategies designed not only to treat these problems when they develop, but also to prevent troublesome complications associated with potential risk factors. In this article, authors classify a wide clinical spectrum of motor complications into different stages as the disease progresses through the treatment. A number of strategies are proposed in order to manage these complications as well as to avoid them. Better understanding of these potential complications will result in better management of these problems and lessen the disability associated with advanced PD.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17897677     DOI: 10.1016/j.jns.2007.08.028

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  19 in total

Review 1.  Epidemiology of Parkinson's disease.

Authors:  Guido Alves; Elin Bjelland Forsaa; Kenn Freddy Pedersen; Michaela Dreetz Gjerstad; Jan Petter Larsen
Journal:  J Neurol       Date:  2008-09       Impact factor: 4.849

2.  Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?

Authors:  Martin Bareš; Irena Rektorová; Robert Jech; Kateřina Farníková; Jan Roth; Evžen Růžička; Petr Kaňovský; Ivan Rektor; Tomáš Pavlík; Leona Uhlířová; Jaroslav Vydlák
Journal:  J Neural Transm (Vienna)       Date:  2011-07-17       Impact factor: 3.575

3.  The effects of BMY-14802 against L-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat.

Authors:  Nirmal Bhide; David Lindenbach; Margaret A Surrena; Adam A Goldenberg; Christopher Bishop; S Paul Berger; Melanie A Paquette
Journal:  Psychopharmacology (Berl)       Date:  2013-02-07       Impact factor: 4.530

4.  Identification of zebrafish A2 adenosine receptors and expression in developing embryos.

Authors:  Wendy Boehmler; Jessica Petko; Matthew Woll; Colleen Frey; Bernard Thisse; Christine Thisse; Victor A Canfield; Robert Levenson
Journal:  Gene Expr Patterns       Date:  2008-12-03       Impact factor: 1.224

5.  Origins and suppression of oscillations in a computational model of Parkinson's disease.

Authors:  Abbey B Holt; Theoden I Netoff
Journal:  J Comput Neurosci       Date:  2014-08-07       Impact factor: 1.621

6.  The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.

Authors:  Melanie A Paquette; Katherine Foley; Elizabeth G Brudney; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Psychopharmacology (Berl)       Date:  2009-03-13       Impact factor: 4.530

Review 7.  Potential influences of complementary therapy on motor and non-motor complications in Parkinson's disease.

Authors:  Theresa A Zesiewicz; Marian L Evatt
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

8.  MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism.

Authors:  Melanie A Paquette; Akari M Anderson; Jason R Lewis; Charles K Meshul; Steven W Johnson; S Paul Berger
Journal:  Neuropharmacology       Date:  2010-01-14       Impact factor: 5.250

9.  Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease.

Authors:  Paulien Gm Ravenstijn; Henk-Jan Drenth; Michael J O'Neill; Meindert Danhof; Elizabeth Cm de Lange
Journal:  Fluids Barriers CNS       Date:  2012-02-08

10.  Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.

Authors:  Cheng-long Xie; Wen-Wen Wang; Su-fang Zhang; Ming-Lu Yuan; Jun-Yi Che; Jing Gan; Lu Song; Wei-En Yuan; Zhen-Guo Liu
Journal:  Sci Rep       Date:  2014-12-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.